Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes.

[1]  G. Campo,et al.  A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study. , 2017, JACC. Cardiovascular interventions.

[2]  P. Serruys,et al.  2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy , 2017, The Lancet.

[3]  R. De Rosa,et al.  Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? , 2017, Journal of thoracic disease.

[4]  J. Mehilli,et al.  Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  J. Tijssen,et al.  Bioresorbable Scaffolds versus Metallic Stents in Routine PCI , 2017, The New England journal of medicine.

[6]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[7]  Hiroki Shiomi,et al.  Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  T. Lüscher,et al.  Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry. , 2016, Cardiology journal.

[9]  Marco Valgimigli,et al.  Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  G. Stone.  Bioresorbable Vascular Scaffolds: More Different Than Alike? , 2016, JACC. Cardiovascular interventions.

[11]  A. Schmermund,et al.  Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. , 2016, Journal of the American College of Cardiology.

[12]  Heribert Schunkert,et al.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials , 2016, The Lancet.

[13]  M. Krucoff,et al.  Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. , 2016, JACC. Cardiovascular interventions.

[14]  P. Serruys,et al.  Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial , 2015, European heart journal.

[15]  W. Cheong,et al.  A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. , 2015, European heart journal.

[16]  W. Cheong,et al.  Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. , 2015, Journal of the American College of Cardiology.

[17]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[18]  G. Stone,et al.  Very Late Thrombosis After Bioresorbable Scaffolds: Cause for Concern? , 2015, Journal of the American College of Cardiology.

[19]  E. Romagnoli,et al.  Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. , 2015, The American journal of cardiology.

[20]  C. Di Mario,et al.  Biodegradable vascular scaffold: is optimal expansion the key to minimising flow disturbances and risk of adverse events? , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[21]  P. Serruys,et al.  A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.

[22]  P. Serruys,et al.  Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary ste , 2015, JACC. Cardiovascular interventions.

[23]  G. Stone,et al.  Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. , 2014, JACC. Cardiovascular interventions.

[24]  G. Gioia,et al.  Pharmacotherapeutic Considerations for the Use of Prasugrel and Ticagrelor to Reduce Stent Thrombosis in Patients With Acute Coronary Syndrome , 2014, Angiology.

[25]  T. Münzel,et al.  Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[26]  F. Piscione,et al.  Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. , 2011, Atherosclerosis.

[27]  Yoshihisa Nakagawa,et al.  Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation , 2010, Circulation. Cardiovascular interventions.

[28]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions : Explanation and Elaboration , 2009 .

[29]  K S Sakariassen,et al.  Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.